Validation of rapid and simple LC-MS/MS method for determination of voriconazole in rat plasma.

[1]  R. Herbrecht,et al.  Clinical pharmacokinetics of voriconazole. , 2006, International journal of antimicrobial agents.

[2]  S. Krähenbühl,et al.  Fast and reliable determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  K. Kümmerer,et al.  Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  B. Keevil,et al.  Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry , 2004, Therapeutic drug monitoring.

[5]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[6]  D. Loebenberg,et al.  Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis , 2004, Antimicrobial Agents and Chemotherapy.

[7]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[8]  J. M. Aguado,et al.  Antifúngicos de uso sistémico , 2003 .

[9]  M. Rinaldi,et al.  Development and Validation of a High-Performance Liquid Chromatography Assay for Voriconazole , 2003, Antimicrobial Agents and Chemotherapy.

[10]  N. Wood,et al.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[11]  D. Andes,et al.  In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[12]  W. Sponsel,et al.  Determination of voriconazole in aqueous humor by liquid chromatography-electrospray ionization-mass spectrometry. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[13]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[14]  M. Brandt,et al.  In Vitro Susceptibilities of CandidaBloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole , 1998, Antimicrobial Agents and Chemotherapy.

[15]  D. Stopher,et al.  A rapid HPLC assay for voriconazole in human plasma. , 1998, Journal of pharmaceutical and biomedical analysis.

[16]  M. Monaco,et al.  Use of Voriconazole in Treatment ofScedosporium apiospermum Infection: Case Report , 1998, Journal of Clinical Microbiology.

[17]  A. Espinel-Ingroff.  In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens , 1998, Journal of Clinical Microbiology.

[18]  M. Vogeser,et al.  Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry , 2005, Clinical chemistry and laboratory medicine.